- Conditions
- Type 2 Diabetes Mellitus, Cardiovascular Disease, Inadequate Glycaemic Control
- Interventions
- Dapagliflozin, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 45 Years and older
- Enrollment
- 964 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 57
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Anaheim, California + 54 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 52
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Type 2 Diabetes
- Interventions
- Saxagliptin, Dapagliflozin, Sitagliptin, Placebo matching with Saxagliptin, Placebo matching with Dapagliflozin, Placebo matching with Sitagliptin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 461 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 40
- States / cities
- Mesa, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 34 more
- Conditions
- Chronic Kidney Disease and Hypertension
- Interventions
- Baxdrostat/dapagliflozin, Dapagliflozin in combination with placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,554 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 114
- States / cities
- Fairhope, Alabama • Phoenix, Arizona • Surprise, Arizona + 97 more
- Conditions
- Heart Failure, Diabetes
- Interventions
- Dapagliflozin, Placebo
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia • New Orleans, Louisiana • Philadelphia, Pennsylvania
- Conditions
- Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)
- Interventions
- Dapagliflozin, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 4,744 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 86
- States / cities
- Fairhope, Alabama • Mobile, Alabama • Sheffield, Alabama + 74 more
- Conditions
- Alzheimer Disease
- Interventions
- Dapagliflozin, Placebo
- Drug · Other
- Lead sponsor
- Jeff Burns, MD
- Other
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Elecoglipron, Dapagliflozin, Elecoglipron-matched placebo, Dapagliflozin-matched placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 27
- States / cities
- Birmingham, Alabama • Daphne, Alabama • Lomita, California + 24 more
- Conditions
- Myocardial Ischemia
- Interventions
- Dapagliflozin 10mg Tab, Placebo
- Drug
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 18 Years to 99 Years · Female only
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- COVID-19
- Interventions
- Dapagliflozin 10 milligram (mg), Placebo
- Drug
- Lead sponsor
- Saint Luke's Health System
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 22
- States / cities
- Fairhope, Alabama • Miami, Florida • Evanston, Illinois + 18 more
- Conditions
- Type 2 Diabetes
- Interventions
- Saxagliptin, Metformin XR, Dapagliflozin, Placebo matching with Dapagliflozin, Placebo matching with Saxagliptin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,282 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 80
- States / cities
- Birmingham, Alabama • Homewood, Alabama • Muscle Shoals, Alabama + 73 more
- Conditions
- Type 2 Diabetes
- Interventions
- Saxagliptin, Dapagliflozin, Metformin IR, Placebo matching with Saxagliptin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 315 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 34
- States / cities
- Birmingham, Alabama • Muscle Shoals, Alabama • Mesa, Arizona + 26 more
- Conditions
- Type 2 Diabetes
- Interventions
- Dapagliflozin, Placebo matching with Dapagliflozin, Saxagliptin, Metformin immediate release (IR)
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 320 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 21 more
- Conditions
- Lupus Nephritis (LN)
- Interventions
- Dapagliflozin (10Mg Tab) along with standard medical therapy, Placebo
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Diabetic Kidney Disease
- Interventions
- MEDI3506, Placebo, Dapagliflozin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 101 Years
- Enrollment
- 609 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 49
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 42 more
- Conditions
- Liver Cirrhosis
- Interventions
- Part A: Placebo (matching zibotentan capsule & matching dapagliflozin tablet), Part A: zibotentan (dose B) + dapagliflozin, Part B: Placebo (matching zibotentan capsule & matching dapagliflozin tablet), Part B: placebo (matching zibotentan capsule) + dapagliflozin, Part B: zibotentan (dose A) + dapagliflozin, Part B: zibotentan (dose B) + dapagliflozin, Part B: zibotentan (dose C) + dapagliflozin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 205 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Pasadena, California • San Francisco, California + 8 more
- Conditions
- Chronic Kidney Disease
- Interventions
- Dapagliflozin, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 4,304 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 55
- States / cities
- Birmingham, Alabama • Hawaiian Gardens, California • Lomita, California + 46 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Elecoglipron, Dapagliflozin, Elecoglipron-matched placebo, Dapagliflozin-matched placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 40
- States / cities
- Huntsville, Alabama • Mobile, Alabama • Sheffield, Alabama + 36 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Dapagliflozin, Placebo
- Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 21 Years to 70 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Type 2 Diabetes
- Interventions
- Dapagliflozin, Placebo matching Dapagliflozin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 2,245 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 155
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 117 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Dapagliflozin, Saxagliptin, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 10 Years to 18 Years
- Enrollment
- 256 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 20
- States / cities
- Sacramento, California • New Haven, Connecticut • Hialeah, Florida + 12 more
- Conditions
- Heart Failure and Impaired Kidney Function
- Interventions
- balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg, balcinrenone/dapagliflozin 40 mg/10 mg and matching placebo for dapagliflozin 10 mg, dapagliflozin 10 mg and matching placebo for balcinrenone/dapagliflozin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 3,850 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 166
- States / cities
- Alexander City, Alabama • Birmingham, Alabama • Fairhope, Alabama + 142 more
- Conditions
- Heart Failure
- Interventions
- Baxdrostat and dapagliflozin, Placebo and dapagliflozin
- Drug · Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 11,300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 198
- States / cities
- Birmingham, Alabama • Centreville, Alabama • Fairhope, Alabama + 176 more
- Conditions
- Type 2 Diabetes Mellitus, Cardiovascular Disease, Hypertension, Inadequate Glycaemic Control
- Interventions
- Dapagliflozin, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 45 Years and older
- Enrollment
- 922 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 60
- States / cities
- Gulf Shores, Alabama • Phoenix, Arizona • Burbank, California + 57 more
- Conditions
- Chronic Kidney Disease and Hypertension
- Interventions
- Baxdrostat/dapagliflozin, Baxdrostat/Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 222 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 17
- States / cities
- Surprise, Arizona • Hollywood, Florida • Port Charlotte, Florida + 14 more